Orexigen Therapeutics Empatic Phase 2B Results Conference Call  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Sep 30 Calls Today's Calls

Call Details Orexigen Therapeutics Empatic Phase 2B Results Conference Call Wed, Sep 30, 2009, 8:30 am Eastern Listen to the archived event audio About Orexigen Therapeutics, Inc. (NasdaqGM:OREX) Other Calls  Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. The company’s lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity. Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California. More Info: Quote | Profile | Reports | Research | Insider | Financials | Analyst Ratings